Crispr Therapeutics (NASDAQ:CRSP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, January 3rd, ValuEngine reports.
A number of other research analysts have also recently commented on the company. Oppenheimer increased their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Goldman Sachs Group increased their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Wells Fargo & Co reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Chardan Capital restated a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Finally, Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Three analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $71.38.
Crispr Therapeutics stock opened at $58.33 on Friday. The stock has a market cap of $3.29 billion, a P/E ratio of -126.80 and a beta of 3.20. Crispr Therapeutics has a fifty-two week low of $29.34 and a fifty-two week high of $74.00. The firm’s fifty day moving average price is $65.14 and its 200-day moving average price is $52.14. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Sell-side analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. 21.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Webster Bank N. A. bought a new position in shares of Crispr Therapeutics during the fourth quarter valued at approximately $26,000. Perigon Wealth Management LLC bought a new stake in shares of Crispr Therapeutics during the fourth quarter valued at approximately $278,000. Farmers & Merchants Trust Co of Chambersburg PA purchased a new stake in Crispr Therapeutics in the fourth quarter worth approximately $26,000. Millennium Management LLC purchased a new stake in Crispr Therapeutics in the third quarter worth approximately $4,366,000. Finally, Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics in the third quarter worth approximately $21,167,000. 49.82% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: What are no-load funds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.